A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 5, 2009, Pages 935-944

  Tse, Archie N ^a   Wu, Nian ^a   Patel, Dina ^a   Haviland, Dana ^a   Kemeny, Nancy ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cholangiocarcinoma; Gemcitabine; Hepatic arterial infusion

Indexed keywords

CREATININE; GEMCITABINE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INFUSION; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LIVER METASTASIS; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSION PUMPS, IMPLANTABLE; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 69249226304     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0945-5     Document Type: Article

References (31)

1. Product information: Gemzar (R), Gemcitabine Eli Lilly (2005)
2. US Food and Drug Administration (2005) Center for drug evaluation and research. Approval summary for gemcitabine for treatment of subjects with locally advanced (nonresectionable stage II or III) or metastatic (stage IV) adenocarcinoma of the pancreas. Available from http://www.foiservices.com
3. NB Ackerman 1974 The blood supply of experimental liver metastases IV. Changes in vascularity with increasing tumor growth Surgery 75 589 596
4. H Anderson N Thatcher J Walling H Hansen 1996 A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer Br J Cancer 74 460 462
5. E Ben-Josef D Normolle WD Ensminger S Walker D Tatro RK Ten Haken J Knol LA Dawson C Pan TS Lawrence 2005 Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies J Clin Oncol 23 8739 8747
6. R Brand M Capadano M Tempero 1997 A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors Invest New Drugs 15 331 341
7. C Breedis C Young 1954 The blood supply of neoplasms in the liver Am J Pathol 30 969
8. BQ Cheng CQ Jia CT Liu W Fan QL Wang ZL Zhang CH Yi 2008 Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial JAMA 299 1669 1677
9. KY Chung N Kemeny 2005 Regional and systemic chemotherapy for primary hepatobiliary cancers and for colorectal cancer metastatic to the liver Semin Radiat Oncol 15 284 298
10. JM Collins 1984 Pharmacologic rationale for regional drug delivery J Clin Oncol 2 498 504
11. WD Ensminger JW Gyves 1983 Clinical pharmacology of hepatic arterial chemotherapy Semin Oncol 10 176 183
12. WD Ensminger A Rosowsky V Raso 1978 A clinical pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2-deoxyuridine and 5-fluorouracil Cancer Res 38 3789 3792
13. Y Fong AM Cohen JG Fortner WE Enker AD Turnbull DG Coit AM Marrero M Prasad LH Blumgart MF Brennan 1997 Liver resection for colorectal metastases J Clin Oncol 15 938 946
14. Jarnagin W, Schwartz L, Gönen M, Gultekin D, Haviland D, Shia J, D'Angelica M, Fong Y, DeMatteo R, Tse A, LH B, NK (2009) Regional chemotherapy for unresectable primary liver cancer: Results of a phase II clinical trial and assessment of dynamic contrast-enhanced MRI as a biomarker of survival (submitted)
15. A Jemal R Siegel E Ward T Murray J Xu MJ Thun 2007 Cancer statistics CA Cancer J Clin 57 43 66
16. N Kemeny W Jarnagin M Gonen et al. 2003 A Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer J Clin Oncol 21 3303 3309
17. NE Kemeny M Gonen 2005 Hepatic arterial infusion after liver resection N Engl J Med 352 734 735
18. NE Kemeny D Niedzwiecki DR Hollis HJ Lenz RS Warren MJ Naughton JC Weeks ER Sigurdson JE Herndon 2nd C Zhang RJ Mayer 2006 Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481) J Clin Oncol 24 1395 1403
19. C Lanz M Fruh W Thormann T Cerny BH Lauterburg 2007 Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC J Sep Sci 30 1811 1820
20. JM Llovet MI Real X Montana R Planas S Coll J Aponte C Ayuso M Sala J Muchart R Sola J Rodes J Bruix 2002 Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 1734 1739
21. LM Pasetto MR D'Andrea C Falci S Monfardini 2007 Gemcitabine in advanced biliary tract cancers Crit Rev Oncol Hematol 61 230 242
22. W Plunkett P Huang CE Searcy V Gandhi 1996 Gemcitabine: preclinical pharmacology and mechanisms of action Semin Oncol 23 3 15
23. 2) levels Invest New Drugs 15 115 121
24. J Schuller J Cassidy E Dumont B Roos S Durston L Banken M Utoh K Mori E Weidekamm B Reigner 2000 Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemother Pharmacol 45 291 297
25. JJ Skitzki AE Chang 2002 Hepatic artery chemotherapy for colorectal liver metastases: technical considerations and review of clinical trials Surg Oncol 11 123 135
26. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
27. JS Tomlinson WR Jarnagin RP DeMatteo Y Fong P Kornprat M Gonen N Kemeny MF Brennan LH Blumgart M D'Angelica 2007 Actual 10-year survival after resection of colorectal liver metastases defines cure J Clin Oncol 25 4575 4580
28. Tse A, Kemeny N (2007) The role of hepatic arterial infusion of chemotherapy in the management of patients with hepatic metastases from colorectal cancer. In: McCulloch P, Karpeh M, Kerr D, Ajani J (eds) Gastrointestinal oncology: evidence and analysis. Informa, New York, pp 179-198
29. AN Tse R Carvajal GK Schwartz 2007 Targeting checkpoint kinase 1 in cancer therapeutics Clin Cancer Res 13 1955 1960
30. TJ Vogl W Schwarz K Eichler K Hochmuth R Hammerstingl U Jacob A Scheller S Zangos M Heller 2006 Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy J Cancer Res Clin Oncol 132 745 755
31. TF Wood DM Rose M Chung DP Allegra LJ Foshag AJ Bilchik 2000 Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications Ann Surg Oncol 7 593 600